Proteolysis targeting chimera activity in human HeLa cells assessed as induction of VCB-mediated delivery of BRD2 for protein degradation by proteasome by measuring drug level causing 50% cellular protein depletion incubated for 24 hrs by Western blotting method
Proteolysis targeting chimera activity in human HeLa cells assessed as induction of VCB-mediated delivery of BRD2 for protein degradation by proteasome by measuring drug level causing 50% cellular protein depletion incubated for 24 hrs by Western blotting method relative to control
Proteolysis targeting chimera activity in human HeLa cells assessed as induction of VCB-mediated delivery of BRD2 for protein degradation by proteasome at 30 to 10000 nM incubated for 24 hrs by Western blotting method
Proteolysis targeting chimera activity in human HeLa cells assessed as induction of VCB-mediated delivery of BRD2 for protein degradation by proteasome at 1 to 10 uM incubated for 24 hrs by Western blotting method
Proteolysis targeting chimera activity in human HeLa cells assessed as induction of VCB-mediated delivery of BRD2 for protein degradation by proteasome at 1 to 10 uM incubated for 6 hrs by Western blotting method
Induction of interaction of N-terminal His6-tagged recombinant human VHL (54 to 213 residues)/elongin C (17 to 112 residues)/elongin B (1 to 104 residues) co-expressed in Escherichia coli BL21 (DE3) with recombinant human Brd2 BD1 assessed as VCB/BRD2/compound ternary complex formation by isothermal titration calorimetry-based assay